Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Track changes in personal budgets to understand drivers, uncover trends, and refine spending and saving habits.
22,888 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A high-quality dividend stock that has fallen 10% can be a rare opportunity. This guide shows you how to evaluate, bu...
Ethereum surged to a six-week high as institutional buying and treasury activity boosted ETH. This article breaks dow...
EchoStar joined the S&P 500 on March 23, 2026, carrying unusually high short interest. This article examines the setu...
A rising iPhone upgrade cycle is quietly lifting a little-known stock. This article breaks down why the move makes it...
A long-running dividend ETF marks 22 years of payments as retirees continue to seek steady income in a shifting marke...
The CLARITY Act aims to separate crypto oversight between the SEC and CFTC while probing foreign adversary risks. Cri...
Dan Firda takes the helm at Brands By Integra, signaling a bold growth push for the 2,000-agent platform. The leaders...
A stock rising 58% this year can signal momentum or a looming reversal. This guide helps you evaluate whether it rema...
As 2026 markets grind higher on slower inflation, investors debate whether a simple, low-cost core holding like VOO r...
As 2026 unfolds, I’m leaning into one magnificent ETF that fits my high-conviction approach. Here’s why this fund sta...
Nike's latest sponsorship moves suggest a gradual return of brand influence and profit potential. This article explor...